AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
A close look at the following two healthcare stocks as the S&P/ASX 200 Health Care Index edged up 0.15% to the current value of 32,355.4 by 47 points.
Bionomics Limited
Bionomics Limited (ASX:BNO) was established in 1998 and is domiciled in Thebarton, Australia. It is a clinical stage biopharmaceutical company that is engaged in extensive research and development to discover and develop novel drug and innovative therapeutics for the treatment of central nervous system disorders and cancer in patients across Australia, the United States and France. Bionomicsâ lead drug candidate BNC210, a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, is currently undergoing Phase 2 trial for the treatment of agitations.
BNC210 is aiming at multi-billion-dollar markets with unmet requirements. The US market potential is illustrated as follows:
Source: Further Analysis of Phase 2 PTSD Trial Results Presentation
With a small market capitalisation of ~ AUD 70.81 million and ~544.69 million outstanding shares, the BNO stock price closed the market trading at AUD 0.135, edging up 3.85% by AUD 0.005 with ~ 292,378 shares traded on 20th May 2019. In addition, the BNO stock price has generated a positive YTD return of 20.93%.
Recently, Bionomics informed that it presented the expanded data from the Phase 2 Post Traumatic Stress Disorder (PTSD) Clinical Trial using BNC210 at the 74th Society of Biological Psychiatry (SOBP) Annual Scientific Conference.
As per the Quarterly Cashflow Report for the three months to 31st March 2019, the company posted cash receipts of $ 1.94 million as compared to $ 2.66 million as on 31st December 2018. Besides, the R&D cost reduced by 62% and the cash balance stood at $ 22.1 million as of the end of quarter.
In addition, Greenhill & Co continued their engagement with Bionomics to assess the strategic options for partnering and portfolio prioritisation.
Auscann Group Holdings Ltd
The Joondalup, Australia-based Auscann Group Holdings Ltd (ASX:AC8) is engaged in research, development, cultivation, production and commercialisation of clinically validated cannabis medicines to patients across Australia. In addition, the Group has a strategic partnership with Tasmanian Alkaloids, one of the largest opium poppy processing companies in the country. Besides, it has additional partners which are as follows:
     
        
Source: Companyâs Website
The Group has a market capitalisation of around AUD 119.04 million, with ~ 309.19 million outstanding shares. The AC8 stock closed the market trading on 20th May 2019 at the last selling price of AUD 0.370, dipping 3.896% by AUD 0.015, with ~ 647,425 shares traded. The stock has a 52-week high of AUD 1.540 and a 52-week low of AUD 0.295.
As per the companyâs quarterly activities report for the three months to March 20th, 2019, Auscann Group Holdings finalised its leadership transition process with the appointment of global pharmaceutical executive Mr. Ido Kanyon as its new CEO, effective May 22nd, 2019.
In addition, the Group continued to broaden its strategic partnerships to diversify the supply of raw materials. AusCann signed a purchase agreement with MediPharm Labs, Canadaâs largest supplier of purified, pharmaceutical grade cannabis extracts, for buying cannabis resin. It also acquired a dedicated 7,300 m2 Research & Development (R&D) facility located in Perth, Western Australia at 5.25 million to support its own product development capabilities. The facility will be upgraded with construction to begin in May and expected to be completed this year.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
